IMV Aktie [WKN DE: A2JLZ3 / ISIN: CA44974L1031]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu IMV Inc Registered Shs

12.05.21		IMV Inc. Announces First Quarter 2021 Financial and Operational Results and Expansion of its Clinical Pipeline (Businesswire)
11.05.21		IMV Appoints Dr. Michael Kalos to Board of Directors (Businesswire)
10.05.21		IMV’s Lead Immunotherapy to be Investigated in Breast Cancer (Businesswire)
13.04.21		IMV Inc. to Present at the Bloom Burton & Co. Healthcare Investor Virtual Conference (Businesswire)
07.04.21		IMV Announces Company-Sponsored Clinical Trial in Patients with r/rDLBCL in Collaboration with Merck Following Feedback from FDA (Businesswire)
25.03.21		IMV Appoints Kyle Kuvalanka to Board of Directors (Businesswire)
17.03.21		IMV Inc. Announces Fourth Quarter and Full Year 2020 Financial and Operational Results (Businesswire)
08.03.21		IMV to Announce Fourth Quarter and Fiscal 2020 Financial and Operational Results and Host Conference Call and Webcast on March 17, 2021 (Businesswire)
01.03.21		IMV to Participate at the upcoming H.C. Wainwright Global Life Sciences Conference (Businesswire)
04.01.21		IMV to Participate in Two Upcoming Investor Events (Businesswire)
28.12.20		IMV Issues Update On Development Of Its COVID-19 Vaccine Candidate - Quick Facts (RTTNews)
28.12.20		IMV Reports Update on COVID-19 Vaccine Program (Businesswire)
06.12.20		Durable Clinical Benefits Induced by IMV’s T Cell Therapy in Combination With Merck’s Keytruda in Subjects With PD-L1 Positive r/r DLBCL Presented at ASH Annual Meeting (Businesswire)
03.12.20		IMV’s Survivin-Targeted T Cell Therapy Shows Durable Clinical Benefits in Phase 2 Study in Patients with Hard-to-Treat Advanced Recurrent Ovarian Cancer (Businesswire)
13.11.20		IMV to Host a Key Opinion Leader Webcast on the Ovarian Cancer Treatment Landscape and Data Highlights from the Phase 2 Trial of a Novel T-Cell Therapy (Businesswire)
12.11.20		IMV Inc. Announces Third Quarter 2020 Financial Results and Provides Clinical Update (Businesswire)
09.11.20		IMV to Participate in Two Upcoming Investor Conferences (Businesswire)
09.11.20		IMV’s T Cell Therapy Demonstrates 86% Objective Response Rate in Combination with Merck’s Keytruda® in PD-L1 Positive Patients with r/r DLBCL (Businesswire)
29.10.20		IMV Inc. to Report Third Quarter 2020 Results and Present Biomarkers Associated With Clinical Response in Patients With r/r DLBCL treated with DPX-Survivac Combination Therapy (Businesswire)
16.10.20		IMV Inc. Re-establishes At-the-Market Facility (Businesswire)
15.10.20		Biomarkers Associated With Clinical Response in Patients With r/r DLBCL Treated With DPX-Survivac Combination Therapy to be Presented at the Upcoming SITC Annual Meeting (Businesswire)
08.10.20		IMV Issues Update On Its COVID-19 Vaccine Program - Quick Facts (RTTNews)
08.10.20		IMV Provides Updates On COVID-19 Vaccine Program (Businesswire)
16.09.20		IMV CEO to Participate at the Vaccines Panel of the Sachs Associates 20th Annual Biotech in Europe Forum (Businesswire)
26.08.20		IMV to Participate at Four Upcoming Investor Conferences (Businesswire)
12.08.20		IMV Inc. Announces Second Quarter 2020 Financial Results (Businesswire)
03.08.20		IMV Inc. to Announce Second Quarter 2020 Results and Host a Conference Call and Webcast on August 12, 2020 (Businesswire)
29.07.20		IMV to Present at BTIG’s Virtual Biotechnology Conference (Businesswire)
20.07.20		IMV Announces Appointment of Michael P. Bailey to Board of Directors (Businesswire)
15.07.20		Pre-market Movers In Healthcare Sector: IMMP, ACOR, CLSN, MRNA, ECOR... (RTTNews)
15.07.20		AZN, IQV Team Up To Accelerate COVID-19 Vaccine Work, RIGL's ITP Drug Repurposed, IMV On Watch (RTTNews)
14.07.20		Stock Alert: IMV Touches New 52-week High On COVID-19 Vaccine Progress (RTTNews)
14.07.20		Stock Alert: IMV Shares Surge 154% On COVID-19 Vaccine Program Update (RTTNews)
14.07.20		IMV Updates Rapid Progress on COVID-19 Vaccine Program (Businesswire)
30.06.20		IMV maintains the remainder of its At-the-Market Facility under its new Base Shelf Prospectus (Businesswire)
29.06.20		IMV Announces Annual and Special Meeting of Shareholders Voting Results (Businesswire)
19.06.20		IMV Files Preliminary Base Shelf Prospectus to Replace Expiring Base Shelf Prospectus (Businesswire)
15.06.20		IMV Announces Leading Independent Proxy Advisory Firms Recommend Shareholders Vote FOR All Resolutions at Upcoming Annual and Special Meeting (Businesswire)
08.06.20		IMV to Present at Raymond James' Human Health Innovation Conference (Businesswire)
29.05.20		At The ASCO: ONCY, IMV, CRDF, GILD, TAK… (RTTNews)
29.05.20		Clinical Response and Translational Data from DeCidE1, a Phase 2 Study of DPX-Survivac Immunotherapy in Patients with Advanced Recurrent Ovarian Cancer (Businesswire)
24.05.20		The Week That Was: COVID-19 Drug/Vaccine Development Landscape (RTTNews)
21.05.20		Stock Alert: IMV Shares Soar 20% In Premarket (RTTNews)
21.05.20		IMV Announces Selection of a Vaccine Candidate Against COVID-19 to Advance Into Human Clinical Studies (Businesswire)
15.05.20		IMV Inc. Provides Clinical and Operational Update and Announces First Quarter 2020 Financial Results (Businesswire)
04.05.20		IMV Inc. to Announce First Quarter 2020 Results and Host a Conference Call and Webcast on May 15, 2020 (Businesswire)
21.04.20		IMV to Participate in Adelaide Capital’s Virtual COVID & Healthcare Mini Conference (Businesswire)
30.03.20		IMV Inc. Announces Fourth Quarter and Full Year 2019 Financial and Operational Results (Businesswire)
30.03.20		IMV Inc. Provides Updates on the Development of DPX-COVID-19 Vaccine and Ongoing Business and Clinical Operations (Businesswire)
25.03.20		IMV to Announce Fourth Quarter and Full Year 2019 Financial and Operational Results and Host Investor Conference Call and Webcast on March 31, 2020 (Businesswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Drohende Korrektur? Experte schlägt Alarm bei der NVIDIA-Aktie

Neuer Rekord nicht mehr weit: Bitcoin, Ethereum, Litecoin & Co.: Wie sich die Kryptokurse am Mittag entwickeln

Pierer Mobility-Aktie zweistellig im Plus: Pierer dementiert Mateschitz-Einstieg bei KTM

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

Angespannte Stimmung in Frankfurt: LUS-DAX gibt am Nachmittag nach

Nah an 100.000er Marke: Bitcoin, Dogecoin, Ethereum & Co. am Vormittag

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	26.11.2024 19:30
Kaufwert:	EUR
	Hinzufügen Speichern